2

Disclaimer

This presentation is prepared by Omkar Speciality Chemicals Limited (OSCL or the “Company”) for general information purposes only, without regard to specific objectives, suitability, financial situations and needs of any particular person and does not constitute any recommendation or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment thereof. This presentation does not solicit any action based on the material contained herein. Nothing in this presentation is intended by the Company to be construed as legal, accounting or tax advice.

This presentation has been prepared by the Company based upon information available in the public domain and its internal estimates. This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any Stock Exchange in India. This presentation may include statements which may constitute forward-looking statements. The actual results could differ materially from those projected in any such forward-looking statements because of various factors. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise.

The information contained in these materials has not been independently verified. None of the Company, its Directors or Promoter(s) or affiliates, nor any of its or their respective employees, advisers or representatives or any other person accepts any responsibility or liability whatsoever, whether arising in tort, contract or otherwise, for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this document or its contents or otherwise in connection with this document, and makes no representation or warranty, express or implied, for the contents of this document including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this document or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. Past performance is not a guide for future performance. The information contained in this presentation are current, and if not stated otherwise, made as of the date of this presentation. The Company undertake no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise. Any person / party intending to provide finance / invest in the shares / businesses of the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision. By attending/perusing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future business of the Company.

This presentation is strictly confidential and may not be copied or disseminated, in whole or in part, and in any manner or for any purpose. No person is authorised to give any information or to make any representation not contained in or inconsistent with this presentation and if given or made, such information or representation must not be relied upon as having been authorized by any person. Failure to comply with this restriction may constitute a violation of the applicable securities laws. This presentation is not intended for distribution or publication in the United States. Neither this document nor any part or copy of it may be distributed, directly or indirectly, in the United States. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about and observe any such restrictions. By participating in this presentation or by reviewing this presentation, you agree to be bound by the foregoing limitations.

This document contains certain forward-looking statements relating to the business, financial performance, strategy and results of the Company and/or the industry in which it operates. Forward-looking statements are statements concerning future circumstances and results, and any other statements that are not historical facts, sometimes identified by the words "believes", "expects", "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements, including those cited from third party sources, contained in this presentation are based on numerous assumptions and are uncertain and subject to risks. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Neither the Company nor its affiliates or advisors or representatives nor any of its or their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. Forward-looking statements speak only as of the date of this presentation. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward looking statements are based.

This presentation is not an offer to sell or a solicitation of any offer to buy the securities of the Company in the United States or in any other jurisdiction where such offer or sale would be unlawful. Securities may not be offered, sold, resold, pledged, delivered, distributed or transferred, directly or indirectly, into or within the United States absent registration under the Securities Act, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Company’s securities have not been and will not be registered under the Securities Act.

The Company’s financial year ends on March 31.

3

OSCL

Lasa Laboratory Pvt. Ltd.

Urdhwa Chemicals

Company Pvt. Ltd.

Rishichem Research Limited

Desh Chemicals Pvt. Ltd.

Company Overview

• Omkar Speciality Chemicals Ltd (OSCL) is involved in the manufacturing of inorganic and organic intermediates and Active Pharmaceuticals Ingredients (APIs)

• OSCL has nine units in the state of Maharashtra, India (five units in Badlapur, District Thane, three units in Chiplun, District Ratnagiri and one unit in Mahad, District Raigad)

• The Company’s product segments include Iodine Compounds, Selenium Compounds, Intermediates, Resolving Agents and Others (Molybdenum, Cobalt, and Bismuth) and APIs which comprises of more than 200 products

• Exports to about 38 countries, including regulated markets such as Europe, North America, South America, China and other Asian countries

Financial Snapshot FY12 FY13 FY14 H1 FY15

Revenue (Rs.Cr.) 166.9 211.7 240.3 120.3

EBITDA (Rs.Cr.) 32.2 40.2 42.9 22.0

Margin 19.9% 19.0% 17.9% 18.3%

PAT (Rs.Cr.) 16.0 20.6 13.6 11.4

Margin 9.4% 9.5% 5.6% 9.4%

Net worth (Rs.Cr.) 105.4 127.0 137.2 159.3

100% 100% 100% 100%

Note: EBITDA calculated as PBT + Depreciation + Finance Costs – Other Income

OSCL and its Subsidiaries

4

Diagnostic Reagents

Cosmetics

Pharmaceuticals

Speciality Coatings

Veternairy API

Catalysis

Glass & Ceramics

Electronics

Synthetic Fibers

Electroplating

Resolving Agents

Feed Nutrients

Applications for our products

5

Evolution Of Company

FY

2010

• Converted into a public limited company • Receives ISO 9001:2008 Certification for Unit II • Receives FDA approval for Unit III, B-34 at Badlapur • Sets up R&D center at Unit III

2011 • Commences operations at Unit III • Lists on BSE and NSE through an Initial Public Offer • Acquires Rishichem Research

2012

• Acquires Desh Chemicals Private Limited • Acquires Urdhwa Chemicals Company Private Limited • Acquires Plot No. D-27/5, at Chiplun • Acquires Plot No. F-9, adjacent to Unit IV at Badlapur • Receives Department of Scientific and Industrial Research ("DSIR") recognition for R&D Center

2013 • Forays into API manufacturing through acquisition of Lasa Laboratory Pvt. Ltd. • Acquires plot No. W-94(A) & W-95(A) adjacent to Unit I at Badlapur • Successful commissioning of Urdhwa Chemicals Plant at Chiplun

2014 • Acquires Plot No. B-15 and B-16 at Chiplun • Acquires Plot No. D-27/4, adjacent to Unit V at Chiplun • Acquires plot No. W-93(A) adjacent to Unit I at Badlapur

6

Business Segments

Iodine Compounds

Anti-diabetic, anti-cancer, anti-cholesterol, etc. & as diagnostic reagents

Resolving Agents

Used in separation of optical isomers during synthesis of bulk drugs

Selenium Compounds

Ingredient for feed nutrient, pharma intermediates, manufacture of tinted glasses and ceramics

Intermediates

Used in pharmaceutical industry in synthesis of various APIs particularly as oxidizing or reducing agents

APIs

Veterinary APIs used mostly as Anthelmintics (de-worming)

130

41

21

10

33

Product usage FY14 Revenue

(Rs. Cr.)*

*Rest of the revenue amounting to ~Rs. 5 Cr is contributed by other products like derivatives of Molybdenum, Cobalt, Bismuth, etc.

7

Business Units

Badlapur Inorganic Intermediates

Badlapur Unit II Organic Intermediates

Badlapur Inorganic Intermediates

Badlapur Centralised warehouse

Unit I

Unit III

Unit IV

Chiplun Organic Intermediates

Chiplun Unit VI Organic Intermediates

Mahad APIs (Veterinary)

Chiplun Organic Intermediates

Unit V

Lasa

Urdhwa

Badlapur Pilot plant for product commercialization Rishi

chem

600

1,025

75

NA

NA

NA

120

2,800

NA

Unit Location Activity undertaken Volumetric Capacities*

*Volumetric capacities as of March 31, 2014

Unit V and Unit VI are proposed manufacturing units

8

Capacity Growth Over The Years

375 375 375 600 600 600 375 375 500

1,025 1,025 1,025

2,800 2,800

0

500

1,000

1,500

2,000

2,500

3,000

3,500

4,000

4,500

5,000

FY09 FY10 FY11 FY12 FY13 FY14

Capacities over the years (MTPA)

Unit I Unit II Unit III Lasa Urdhwa

Volumetric Capacity (MTPA)

FY09 FY10 FY11 FY12 FY13 FY14

Unit I 375 375 375 600 600 600

Unit II 375 375 500 1,025 1,025 1,025

Unit III - - 75 75 75 75

Lasa - - - - 120 120

Urdhwa - - - - 2,800 2,800

Total Capacity

750 750 950 1,700 4,620 4,620

9

Strengths

Fungible Facilities leading to multi

product capability

Diversified customer base

• Manufacturing facilities with multiple product capability

• Products across segments comprise of more than 200 products

• OSCL can change its product mix with minimum lead time

Long standing existing client relationships

• Existing client relationships in domestic and international markets

• Of the top 30 customers over the past 2 fiscal years, more than 40% have been repeat customers

Cost advantage backed by a strong

focus on R&D

• Developed processes for manufacture of products in a cost effective manner

• DSIR recognized R&D unit

• Acquired Rishichem Research Limited – unit equipped with pilot plant facilities

Quality control

• OSCL has quality control departments at each of its units

• Activities comprise sampling, testing of raw materials and processes, quality certification, etc.

Experienced management

team and employees

• Managed by a team of qualified and experienced management and technical teams

• OSCL believes that the strength and quality of its management team has been instrumental in implementing its business and growth strategies successfully

• Diverse customer base from different industry segments

• In FY14, OSCL’s top 30 customers contributed less than 60% of the total sales, with the largest customer contributing 6.03% of the total sales

1 2 3 4 5 6

10

Markets Served

Currently OSCL has footprints across 38 countries round the globe

11

Strategy

Product range expanded from around 90 products in FY11 to more than 200 products currently

Acquired Lasa Labs in FY13 to enter into the API segment In the past, OSCL has increased its manufacturing capacity from 750 MTPA in FY09 to

4,620 MTPA in FY14. Going forward, it intends to increase its manufacturing capacity by more than 100% and

for this purpose, it has already incurred substantial amount of capital expenditure in the past fiscal years

Augmenting manufacturing capacity to increase product range

OSCL has an export presence in about 38 countries, including regulated markets such as Europe, North America, South America, China and other Asian countries

Exports as a % of gross sales increased from 15.1% in FY12 to 23.8% in FY14 OSCL intends to increase its presence outside India, both in terms of value and markets,

by leveraging its expertise and cost competitiveness to attract new customers in different geographies

Increase in exports

Applications for registration of 14 process patents of which 2 have been granted viz. process for producing 5-Iodo-2-Methylbenzoic Acid and process for producing Benzene Seleninic Anhydride

The receipt of such process patents prohibits the use of the same process for manufacture of the said product by anyone else

Process patents for key products

12

Strategy (continued)

To add value to its operations and yield better performance going forward Enables the Company to become cost competitive whereby it would be manufacturing

intermediates for the APIs that it develops Reduce the Company's dependence on suppliers of certain raw materials as well as

customers for certain end-products

Focus on backward and forward integration

Innovation will enable Company to grow its business in size as well as profitability and will assist it in addressing challenges occurring due to economic factors

Innovation to also focus on addressing a significant part of the value chain: From being present through forward integrations in APIs (through the acquisition of

Lasa Labs and the subsequent capacity expansions) on the back of in-house intermediates and;

To setting up manufacturing facilities which are fungible so as to meet the fast changing needs of customers with minimum lead time

Focus on innovation

OSCL manufactures high value niche products as well as high volume commoditized products

A concerted effort undertaken by OSCL to focus on higher margin segments like Intermediates and APIs

The acquisition of Lasa Laboratory Private Limited was in this direction, for entering into the API market on the back of OSCL’s in-house intermediates

The share of intermediates and APIs as a % of the total net sales & services increased from 10.0% in FY13 to 17.2% in FY14 and from 5.1% in FY13 to 13.6% in FY14 respectively

The Company intends on maintaining a judicious mix of products so that growth is not compromised for profitability and vice versa

Reduce risks associated with our business by growing in the high margin niche products and also maintaining a portfolio of high volume commoditized products simultaneously

13

Promoters & Directors

Mr. Pravin Herlekar

Chairman & Managing Director

He is a Bachelor of Technology in Chemical Engineering from Indian Institute of Technology, Bombay

He has an overall experience of 40 years in the field of Product Development, Marketing and Administration

He has been actively involved in the business of the Company and has played a key role in the growth of OSCL with his inputs in strategic planning and business development

Over the years he has been successful in expanding OSCL’s customer base, especially in Europe, North America, Asia, South America & Australia

Mr. Omkar Herlekar

Whole-time Director

He is a Bachelor of Science and Master of Science (By Research) in Chemistry from the University of Mumbai and has an overall experience of 8 years

He looks after the Research & Development activities of OSCL and supervises the entire factory operations

He is actively involved in the setting up and implementation of OSCL’s new manufacturing units

14

Directors

Prof. Dr. Suhas Rane Independent Director

Mrs. Anjali Herlekar Non-executive, Promoter And Woman Director

Mr. Amit Pandit Independent Director

Dr. Vikas Telvekar Independent Director

Mr. Siddharth Sinkar Non-independent Non Executive Director

Mr. Subhash Mali Independent Director

Dr. Rane is a BE Mechanical Engineer, Diploma in Management Studies (DMS)and Master of Financial Management (MFM) from Mumbai University

Mrs. Herlekar has been recently inducted on to the board

Mr. Pandit is a Fellow Member of the Institute of Chartered Accountants of India (ICAI), holds a Diploma in Business Finance (DBF) and is a commerce graduate from University of Bombay

Mr. Sinkar is a Fellow Member of the Institute of Chartered Accountants of India (ICAI), and a commerce graduate from Mumbai University

Dr. Telvekar is a Master of Science (Technology) and Doctor of Philosophy (Technology) in Pharmaceutical and Fine Chemicals from UDCT, Mumbai

Mr. Mali is a Bachelor of Chemical Engineering from University of Bombay

15

Consolidated Financial Snapshot

166.9

211.7

240.3

120.3

FY12 FY13 FY14 H1 FY15

Revenue (Rs.Cr.)

32.2

40.2 42.9

22.0

19.9%

19.0% 17.9% 18.3%

14.0%

14.5%

15.0%

15.5%

16.0%

16.5%

17.0%

17.5%

18.0%

18.5%

19.0%

19.5%

20.0%

20.5%

0

5

10

15

20

25

30

35

40

45

50

FY12 FY13 FY14 H1 FY15

EBITDA (Rs.Cr.)

16.0

20.6

13.6

11.4

9.4% 9.5%

5.6%

9.4%

0.0%

1.0%

2.0%

3.0%

4.0%

5.0%

6.0%

7.0%

8.0%

9.0%

10.0%

0

5

10

15

20

25

FY12 FY13 FY14 H1 FY15

PAT(Rs.Cr.)

Note: EBITDA calculated as PBT + Depreciation + Finance Costs – Other Income using the respective numbers for financial years 2012, 2013, and 2014 ended March 31 and limited review report as of September 30, 2014

Revenue from Operations (Rs. Cr.) EBITDA (Rs. Cr.)

PAT (Rs. Cr.) Net Worth (Rs. Cr.)

105.4

127.1 137.2

159.3

FY12 FY13 FY14 H1 FY15

BEST EMERGING SME AWARD, 2013 TO OSCL

THANK YOU

Visit us at

www.omkarchemicals.com